Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Briefing.com reports. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The business […]

Pinnacle Associates Ltd. lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 3.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 176,124 shares of the biopharmaceutical company’s stock after purchasing an additional 5,055 shares during the quarter. Pinnacle Associates […]